Bouchal Jan Ph.D., Assoc. Prof.
Journals
BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.
Tumor Biology.
2015,
36(6),
4243-52,
ISSN: 1010-4283,
PMID: 25616695,
TMPRSS2-ERG gene fusion in prostate cancer.
Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czech Republic.
2014,
158(4),
502-510,
ISSN: 1213-8118,
PMID: 25485532,
Triple negative breast cancer-BCL2 in prognosis and prediction. Review.
Current Drug Targets.
2014,
15(12),
1166-1175,
ISSN: 1389-4501,
PMID: 25374001,